Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by WestEnd Advisors LLC

WestEnd Advisors LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 43.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 27,947 shares of the biopharmaceutical company’s stock after purchasing an additional 8,528 shares during the period. WestEnd Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $21,194,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. SYM FINANCIAL Corp grew its stake in shares of Regeneron Pharmaceuticals by 25.1% in the 3rd quarter. SYM FINANCIAL Corp now owns 718 shares of the biopharmaceutical company’s stock valued at $544,000 after buying an additional 144 shares during the period. Oakworth Capital Inc. raised its position in shares of Regeneron Pharmaceuticals by 25.0% during the 3rd quarter. Oakworth Capital Inc. now owns 70 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 14 shares during the period. Ashton Thomas Securities LLC raised its position in shares of Regeneron Pharmaceuticals by 24.6% during the 3rd quarter. Ashton Thomas Securities LLC now owns 1,706 shares of the biopharmaceutical company’s stock valued at $1,294,000 after buying an additional 337 shares during the period. Penobscot Investment Management Company Inc. acquired a new position in Regeneron Pharmaceuticals in the third quarter valued at approximately $243,000. Finally, Oppenheimer & Co. Inc. lifted its holdings in Regeneron Pharmaceuticals by 1.9% in the third quarter. Oppenheimer & Co. Inc. now owns 22,555 shares of the biopharmaceutical company’s stock valued at $17,103,000 after acquiring an additional 426 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, insider Andrew J. Murphy sold 4,147 shares of the company’s stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total value of $3,204,386.90. Following the completion of the transaction, the insider owned 47,833 shares in the company, valued at $36,960,559.10. This represents a 7.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. The trade was a 31.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 8,093 shares of company stock valued at $6,506,845 in the last quarter. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $816.10 on Wednesday. The stock has a market capitalization of $84.02 billion, a PE ratio of 20.17 and a beta of 0.16. Regeneron Pharmaceuticals, Inc. has a 1 year low of $591.52 and a 1 year high of $859.34. The company’s 50-day simple moving average is $791.66 and its 200-day simple moving average is $737.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating the consensus estimate of $10.16 by $4.13. The business had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. The company’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period in the previous year, the business posted $12.81 EPS. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 49.10 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were issued a dividend of $0.94 per share. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is 9.29%.

Analysts Set New Price Targets

Several research analysts recently weighed in on REGN shares. Jefferies Financial Group increased their price objective on Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Robert W. Baird raised their target price on Regeneron Pharmaceuticals from $742.00 to $761.00 and gave the stock a “neutral” rating in a research note on Friday, July 31st. Argus upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 target price on the stock in a research report on Thursday, October 1st. Evercore upped their price target on Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. Finally, Cantor Fitzgerald increased their price target on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $846.28.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron extended its agreement with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to supply additional doses of Inmazeb, its Ebola treatment. The extension adds approximately $270 million in value and supports near-term revenue visibility. Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb for U.S. Preparedness
• Positive Sentiment: Strong third-quarter results from partner Kiniksa highlighted growing demand and blockbuster potential for Arcalyst, which is partnered with Regeneron. The update may reinforce expectations for increased royalty or collaboration-related contributions. Kiniksa jumps as Q3 results show blockbuster prospects for Regeneron-partnered Arcalyst
• Positive Sentiment: Regeneron released nearly four years of survival-benefit data for Libtayo, its cancer immunotherapy. Durable efficacy could support the drug’s commercial positioning and future adoption. Regeneron Pharmaceuticals Posts Nearly Four Years of Survival Benefit Data for Libtayo
• Neutral Sentiment: Analysts expect third-quarter earnings of approximately $16.19 per share, with results due October 30. Investors are also focused on Regeneron recording its full share of Dupixent profits with Sanofi for the first time, a potentially significant earnings catalyst but one already receiving attention ahead of the report. Regeneron Q3 earnings preview
• Neutral Sentiment: Recent commentary describes REGN as an increasingly diversified investment and a strong value stock. Reported short interest of zero shares provides no meaningful bearish signal, although the figure may reflect a data-reporting issue rather than actual market positioning. Has Regeneron Stock Become a Different Bet?

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.